Uncontrolled macrophage functions cause failure to resolve gut inflammation and has been implicated in the pathogenesis of inflammatory bowel disease (IBD). 15-Deoxy-Δ^{12,14}-prostaglandin J₂ (15d-PGJ₂), one of endogenous lipid mediators formed from arachidonic acid during the inflammatory process, has been reported to terminate inflammation. However, the pro-resolving effect of 15d-PGJ₂ on intestinal inflammation and underlying molecular mechanisms remain largely unknown. In the present study, we examined the effects of 15d-PGJ₂ on the resolution of dextran sulfate sodium (DSS)-induced murine colitis that mimics human IBD. Pharmacologic inhibition of prostaglandin D synthase (PGDS) responsible for the synthesis of 15d-PGJ₂ hampered resolution of inflammation in the colonic mucosa of mice treated with DSS. Notably, intraperitoneal injection of 15d-PGJ₂ accelerated the resolution of experimentally induced colitis. 15d-PGJ₂ treatment reduced the number of neutrophils and M₁ macrophages, while it increased the proportion of M₂ macrophages. Moreover, 15d-PGJ₂ treated mice exhibited the significantly reduced proportion of macrophages expressing the pro-inflammatory cytokine, IL-6 with concomitant suppression of STAT3 phosphorylation in the colonic mucosa of mice administered 2.5% DSS in drinking water. Taken together, these findings clearly indicate that 15d-PGJ₂, endogenously generated from arachidonic acid by cyclooxygenase-2 and PGDS activities in inflamed tissue, promotes resolution of intestinal colitis.

**Keywords:** cyclopentenone prostaglandin, resolution of intestinal inflammation, macrophage polarization, DSS-induced colitis, STAT3, 15-deoxy-Δ^{12,14}-prostaglandin J₂

**INTRODUCTION**

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic disorder characterized by inflammation of the gastrointestinal tract typically with a relapsing and remitting clinical course (1, 2). In IBD, the immune response is initiated by the interaction among the components of the innate immune system, including macrophages and dendritic cells (3).
In particular, mucosal macrophages represent the largest population of mononuclear phagocytes in the intestine and play an important role in the mucosal immune system (4). Inappropriate macrophage activation has been implicated as one of major reasons for failure to resolve acute inflammation in the gut (5). Thus, attention has been focused on controlling dysregulated functions of macrophages, which could augment development of IBD. The relapsing inflammatory disorders are associated with sustained overproduction of pro-inflammatory cytokines in the intestinal lamina propria (6). Intriguingly, in the inflamed gut of patients with IBD, activated macrophages produce significantly more pro-inflammatory cytokines such as TNF-α, IL-23 and IL-6 (7).

The transcription factor STAT3 that plays a key role in inflammation and immunity is activated by IL-6 family cytokines (8). Prolonged or excessive inflammatory response through STAT3 overactivation contributes to chronic inflammation, resulting in an inflammatory disorder and colorectal cancer. Phosphorylation of STAT3 on tyrosine 705 facilitates its dimerization and translocation into nucleus, where it regulates transcription of genes involved in inflammation (9). It has been reported that increased STAT3 phosphorylation is found in the dextran sulfate sodium (DSS)-induced murine model as well as in inflamed colon mucosa of IBD patients (10, 11). Genome-wide association studies have revealed that STAT3 gene is one of the susceptibility loci in IBD (12). Moreover, persistent activation of STAT3 is implicated in IBD and colorectal cancer (13, 14).

The process of resolution is actively controlled by endogenous anti-inflammatory and pro-resolving mediators (15). Prostaglandins (PGs) are key mediators of inflammation. Their production changes during the different stages of inflammation. PGE2 and PGI2 are generated to initiate inflammation, while cyclopentenone PGs are produced to terminate inflammation in the later phase of acute inflammation. Cyclopentenone PGs have immunomodulatory and anti-inflammatory effects to switch off inflammatory response. Thus, a shift from PGE2 to cyclopentenone PGs contributes to resolution of inflammation (16).

15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), a representative J-series cyclopentenone PG, plays important roles in regulating inflammation through inhibition of pro-inflammatory signaling. The biosynthesis of 15d-PGJ2 is initiated by cyclooxygenase-2 (COX-2) and subsequently regulated by the prostaglandin D synthase (PGDS) activity. PGDS has two distinct isoforms, hematopoietic PGDS (HPGDS) and lipocalin PGDS (LPGDS). 15d-PGJ2 inhibits nuclear factor-kappa B (NF-kB)-mediated expression of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 in endothelium and the pro-inflammatory enzymes, inducible nitric oxide synthase (iNOS), and COX-2 (17–19). 15d-PGJ2 has both anti-inflammatory and pro-resolving activities (20, 21). Although 15d-PGJ2 has been reported to protect against acute inflammatory tissue injury (22), detailed molecular mechanisms underlying its pro-resolving effect in intestinal inflammation remain largely unknown. Here, we report that 15d-PGJ2 promotes resolution of DSS-induced colitis.

**MATERIALS AND METHODS**

**Animals**

Male C57BL/6 mice (5 weeks of age) were purchased from Central Lab. Animal, Inc. (Seoul, South Korea). They were acclimated for 7 days with tap water and a pelleted basal diet before the start of the experiments. The animals were housed in plastic cages under controlled conditions of temperature (23°C ± 2°C), humidity (50% ± 10%), and light (12/12-h light/dark cycle).

**DSS-Induced Colitis**

To induce colitis, mice were given drinking water containing 2.5% DSS (MW 36,000–50,000; MP Biomedicals) for 7 days. For evaluation of colitis resolution, mice received normal drinking water for additional 15 days. 15d-PGJ2 (2 mg/kg/day) suspended in 10% DMSO in phosphate-buffered saline (PBS) or vehicle was administered intraperitoneally. Mice were euthanized by CO2 asphyxiation, and their colorectal parts were taken out, cut longitudinally, and washed with PBS. For histopathological examination, the distal section of colon tissues was fixed in 10% buffered formalin, whereas another portion was flash-frozen in liquid nitrogen and kept at -70°C for further analysis.

**Tissue Lysis and Protein Extraction**

Colon tissues were homogenized in an ice-cold lysis buffer [150 mM NaCl, 0.5% Triton-X 100, 50 mM Tris–HCl (pH 7.4), 20 mM EGTA, 1 mM dithiothreitol (DTT), 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), and EDTA-free protease inhibitor cocktail tablet], followed by a periodical vortex mixing for 30 min at 4°C. The lysates were centrifuged at 14,000 rpm for 15 min at 4°C. The supernatants were collected and stored at -70°C until use.

**Western Blot Analysis**

For Western blot analysis, the total protein concentration was quantified by using the bicinchoninic acid (BCA) protein assay kit (Pierce). Cell lysates (20–50 μg protein) were mixed and boiled in a sodium dodecyl sulfate (SDS) sample buffer for 5 min at 95°C before 8%–17% SDS–polyacrylamide gel electrophoresis (SDS-PAGE). They were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Gelman Laboratory). The blots were blocked in 5% fat-free dry milk in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 h at room temperature. The membranes were incubated for 12 to 24 h at 4°C with primary antibodies for HPGDS, LPGDS, COX-2 (Cayman Chemical), P-STAT3, STAT3 (Cell Signaling Technology), and actin (Sigma Aldrich). Antibodies directed against HPGDS, LPGDS, COX-2, and P-STAT3 were diluted at 1:1,000 and anti-actin antibody was diluted at 1:3,000. The membranes were washed, followed by incubation with 1:3,000 dilution of respective horseradish peroxidase (HRP)-conjugated secondary antibodies (rabbit or mouse) (Zymed Laboratories) for 1 h, and then washed with TBST. Protein expression was visualized with an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech) and ImageQuant LAS-4000 (GE Healthcare) according to the manufacturer’s instructions.
Immunohistochemical Analysis and Immunofluorescence Staining

The dissected colon tissues were prepared for immunohistochemical and immunofluorescence analyses of the expression of P-STAT3 and COX-2, respectively. Four to 10 μm sections of 10% formalin-fixed, paraffin-embedded tissues were cut and mounted onto glass slides, deparaffinized three times with xylene and rehydrated through graded alcohol bath. The deparaffinized sections were heated by using microwave and boiled twice for 6 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval. To diminish nonspecific staining, each section was treated with 3% hydrogen peroxide and 4% peptone casein blocking solution for 15 min. For detection of P-STAT3, slides were incubated with anti-P-STAT3 antibody at room temperature for 40 min in Tris-buffered saline containing 0.05% Tween 20, and then developed using respective HRP-conjugated secondary antibodies (rabbit) EnVision™ System (Dako). The peroxidase binding sites were detected by staining with 3’,3’-diaminobenzidine tetrahydrochloride. Finally, counterstaining was performed using Mayer’s hematoxylin. For immunofluorescence analysis of COX-2, the slides were stained with anti-COX-2 antibody in 5% bovine serum albumin at 4°C overnight and then washed 3 times. The slides were then incubated with fluorophore-conjugated secondary antibody (Alexa Fluor 488) for another 1 h at room temperature. Nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). The fluorescent images were visualized under a confocal microscope.

Isolation of Murine Lamina Propria Immune Cells From Colonic Tissues

Isolation of colonic lamina propria cells was performed according to the protocol (23). Entire colons from each group were longitudinally cut and washed to remove feces. They were then cut into 1 cm pieces, followed by incubation with predigestion solution containing 5 mM EDTA and 0.145 mg/ml DTT for 20 min at 37°C on a shaking platform. After removal of EDTA by three washes in PBS and passing through a cell strainer (100 μm), the suspension of epithelial, subepithelial, and villus cells were removed. The remaining colon pieces including lamina propria cells and muscle layer were cut by using scissors, and then incubated in digestion media containing 0.05 g of collagenase D (Roche), 0.05 g of DNase I (Sigma-Aldrich) and 0.3 g of dispase II (Roche) for 25 min at 37°C on a shaking platform. After digestion, the lamina propria cells were enriched using Percoll density gradient centrifugation. The resulting cells were then used for flow cytometry analysis.

Flow Cytometry

Lamina propria cells were stained with a cocktail of antibodies to various markers including CD45, F4/80, CD11b, CD86, CD206, and Gr-1 for 30 mins at 4°C. For intracellular staining, cells were stained with cell surface markers, and incubated Fixation/Permeabilization working solution to each sample for fixation and permeabilization according to the manufacturer’s instructions. The cells were stained with antibody specific to IL-6 for 1 h at 4°C and subjected to flow cytometry. The results were analyzed using FlowJo software.

Preparation of Bone Marrow Derived Macrophages (BMDMs)

Bone marrow cells were isolated from femurs and tibias of C57BL/6 mice. BMDMs are differentiate from bone marrow cells in RPMI1640 medium supplemented with 10% fetal bovine serum and 20 ng/ml M-CSF for 7 days. After removal of non-adherent cells, BMDMs were detached from the plate using Accutase (Innovative Cell Technologies) and used for the further experiments. To induce M1 macrophage polarization, BMDMs were stimulated with bacterial lipopolysaccharide (LPS; 100 ng/ml) for 4 h.

Real-Time RT-PCR

Total RNA was isolated from BMDM or mouse colon tissues using TRIzol® according to the manufacturer’s instruction. RNA was then used to synthesize complementary DNA (cDNA) and further analyzed by using RealHelix qPCR kit (Nanohelix) with Applied Biosystems 7500 Fast Real-Time PCR System following the manufacturer’s instructions.

Statistical Analysis

All data are expressed as means ± SD of at least three independent experiments, and statistical analysis was performed using ANOVA. The criterion for statistical significance was *p < 0.05, **p < 0.01, and ***p < 0.001.

RESULTS

15d-PGJ2 Is Produced During Resolution of Intestinal Inflammation

To investigate resolution of intestinal inflammation, the DSS-induced colitis model was used. Mice were given drinking water containing 2.5% DSS for 7 days, which causes severe inflammatory damage to colonic epithelium (24). Mice were then exposed to normal drinking water after 15 days to allow intestinal inflammation to subside (Figure 1A). Mice began to lose body weight after 5 days of DSS treatment, and the body weight loss continued 3 days following termination of DSS exposure (Figure 1B). Mice restored the body weight from day 11. The weight loss of the mice associated with intestinal inflammation was completely recovered after 15 days of drinking normal water (Figure 1B). DSS-treated mice demonstrated acute colitis with massive colon ulceration, crypt damage, and severe inflammation. Based on the severity of stool consistency and rectal bleeding, pathogenic conditions were scored from 0 to 3. The sum was given into a form of the disease activity index (DAI). Mice administered DSS exhibited severe symptoms with liquid stool and large amount of rectal bleeding. DAI score reached a maximal level on day 10, and gradually decreased during the resolution phase (Figure 1C). In addition, mice exposed to DSS displayed shortening of the colon length, but this was mostly recovered by the end of experiment (Figure 1D). We also performed histological evaluation of dysplasia in the colonic mucosa by hematoxylin and eosin (H&E) staining. Exposure to DSS almost completely destroyed the architecture of colonic mucosa, but this was eventually recovered (Figure 1E).
15d-PGJ2 is formed from arachidonic acid during inflammatory response (25). To assess the possible involvement of 15d-PGJ2 in adaptive survival response to DSS-induced colitis, the expression of HPGDS and LPGDS as well as COX-2 was measured during onset and resolution of inflammation. COX-2 expression was increased in the late phase of inflammation, and decreased thereafter during the resolution phase of inflammation (Figure 1F). Notably, HPGDS expression was significantly upregulated, while LPGDS expression was barely changed during the resolution of inflammation (Figure 1F).

### Inhibition of HPGDS Exacerbates DSS-Induced Colitis

HPGDS converts PGH2 formed by COX-2 to PGD2, an intermediate in 15d-PGJ2 biosynthesis. The increased expression of HPGDS hence results in enhanced production of 15d-PGJ2, which plays an essential role in regulating immune response for its cytoprotective effects (26, 27). In order to determine whether the pro-resolving effects of endogenous 15d-PGJ2 on DSS-induced colitis attributable to HPGDS, we utilized HQL-79, a commonly used inhibitor of this enzyme (28, 29). The mice were given 2.5% DSS in drinking water ad libitum for 10 days. HQL-79 (30 mg/kg) was given via gavage during the subsequent resolution phase (Figure 2A). Under these conditions, HQL-79 treated mice exhibited a significant decrease in survival (Figure 2B). In addition, pharmacologic inhibition of HPGDS activity severely compromised resolution of intestinal inflammation. Thus, HQL-79 administration abrogated recovery of body weight (Figure 2C) and aggravated the severity of diarrhea and rectal bleeding (Figure 2D). Furthermore, mice treated with the HPGDS inhibitor were not able to recover DSS-induced shortening of the colorectal length, compared with those treated with vehicle (Figure 2E). These data demonstrate that 15d-PGJ2 plays an important role in resolution of intestinal inflammation.

### 15d-PGJ2 Promotes Recovery of DSS-Induced Colitis in Mice

Next, we assessed the effect of exogenous 15d-PGJ2 on the resolution of DSS-induced colitis. For this purpose, mice were treated with 2.5% DSS in drinking water ad libitum for 7 days and then divided into two groups. One group of mice was allowed to resolve intestinal inflammation for an additional 4 days on normal drinking water, while the other group received 15d-PGJ2 (2 mg/kg) 4 times intraperitoneally during the same period (Figure 3A). Mice administered 15d-PGJ2 exhibited significantly improved body weight recovery, compared with mice given vehicle (Figure 3B). In addition, 15d-PGJ2 administration ameliorated the severity of diarrhea and rectal bleeding (Figure 3C) and recovered DSS-induced shortening of the colorectal length (Figure 3D). These data suggest that 15d-PGJ2 stimulates resolution of the DSS-induced colitis in mice.

### 15d-PGJ2 Induces Macrophage Polarization During Resolution of DSS-Induced Murine Colitis

Macrophages play a key role in controlling the onset and the resolution of acute inflammation (30). Macrophages are classified into two types, classically activated (M1) macrophages and alternatively activated (M2) macrophages. The M1 macrophages...
produce pro-inflammatory cytokines and reactive nitrogen and oxygen intermediates, resulting in inflammation. In contrast, the M2 macrophages have anti-inflammatory and pro-resolving properties, which are involved in enhancement of phagocytic activity, tissue remodeling, etc (31). As an initial step towards investigating the effects of 15d-PGJ2 on mobilization of macrophages, leukocytes infiltrated to the lamina propria (CD45+) were isolated from colon tissue as depicted in Supplementary Figure 1A. While the proportion of infiltrated leukocytes (CD45+) was significantly increased as a consequence of intestinal inflammation caused by DSS, this was decreased during the resolution phase following 15d-PGJ2 treatment (Supplementary Figure 1B).

Next, we determined the proportion of macrophages by flow cytometry. The number of neutrophils (CD45+ CD11b+ Gr-1+) was significantly increased as a consequence of intestinal inflammation caused by DSS, and this was decreased during the resolution phase following 15d-PGJ2 treatment (Supplementary Figure 1B).
Gr-1(-) F4/80(-) CD206(-)) during the resolution of intestinal inflammation in lamina propria of 15d-PGJ2-treated mice decreased significantly, compared with the vehicle control. The proportion of macrophages (CD45+ CD11b+ Gr-1(-) F4/80+ CD86+) was elevated during the inflammatory phase, but reduced in both groups during the resolution phase (Figure 4A). Considering the differential roles for macrophages in the inflammation and its resolution, we then measured the proportions of M1 and M2 macrophages of colonic mucosa by flow cytometry. As shown in Figure 4B, 15d-PGJ2 administration lowered the proportion of M1 macrophages (CD45+ CD11b+ Gr-1(-) F4/80+ CD86+) while it significantly enhanced that of M2 macrophages (CD45+ CD11b(-) Gr-1(-) F4/80(-) CD206+) during the resolution of intestinal inflammation (Figure 4C).

Macrophages that infiltrate the inflamed tissue are derived from bone marrow precursors that migrate via the peripheral circulation. To further examine the effect of 15d-PGJ2 on macrophage polarization more systematically, BMDMs isolated from the same strain of mice used for inducing colitis were stimulated with LPS, which has been known to induce the M1 polarization. LPS treatment upregulated the mRNA expression of M1 markers including iNOS, IL-1β, and IL-12. 15d-PGJ2 (10 μM) significantly inhibited the expression of M1 markers in LPS-stimulated macrophages (Figure 4D). In addition, we investigated whether 15d-PGJ2 could affect M2 macrophage polarization. 15d-PGJ2 alone could not significantly induce expression of M2 macrophage markers, but synergistically increased M2 macrophage polarization when BMDMs were co-treated with IL-4, a known inducer of M2 makers (Figure 4E). These findings suggest that 15d-PGJ2 regulates leukocyte trafficking and renders macrophages polarized into the M2 phenotype while it suppresses manifestation of the M1 phenotype.

15d-PGJ2 Inhibits IL-6 Expression and STAT3 Activation During Resolution of DSS-Induced Intestinal Inflammation

Increased pro-inflammatory cytokine production is a hallmark of intestinal inflammation (32, 33). In particular, overproduction of IL-6 has been reported to trigger chronic intestinal inflammation and subsequently colon cancer. In order to determine whether the pro-resolving effects of 15d-PGJ2 are associated with inhibition of IL-6 in macrophages, mice were given 2.5% DSS in drinking water for 7 days, followed by normal water for another 6 days to allow resolution of acute intestinal inflammation (Figure 5A). When the mice were given normal water, 15d-PGJ2 was administrated on daily basis into peritoneum of mice. DSS-induced intestinal inflammation were significantly ameliorated in 15d-PGJ2-treated mice, as indicated by the improvement of body weight loss (Figure 5B), DAI score (Figure 5C), shortening of colon length (Figure 5D), and disruption of crypt architecture (Figure 5E). Next, macrophages expressing IL-6 were selectively identified by flow cytometry. 15d-PGJ2 inhibited the proportion of macrophages expressing IL-6 (CD45+ CD11b+ Gr-1(-) F4/80(-) IL-6+) during resolution of intestinal inflammation (Figure 5F).

STAT3, a representative transcription factor involved in intestinal inflammation, is mainly activated by IL-6 (34). One of the key events in activation of STAT3 is its phosphorylation on the tyrosine 705 (Y705) residue. 15d-PGJ2 administration given during the resolution phase markedly inhibited DSS-induced inflammation. To further examine the effect of 15d-PGJ2 on STAT3 phosphorylation, BMDMs isolated from the same strain of mice used for inducing colitis were co-cultured with IL-4 and 15d-PGJ2 for 4 h. The mRNA levels of M2 markers including Arg-1, CD36, TGF-β, and YM-1 were determined by real-time PCR. 15d-PGJ2 administration markedly inhibited DSS-induced inflammation.
phosphorylation of STAT3 in colonic mucosa (Figure 6A). It also abolished the DSS-induced expression of COX-2 (Figure 6A), a principal pro-inflammatory enzyme frequently overexpressed in the inflamed colonic mucosa of patients with IBD (35, 36). The inhibitory effects of 15d-PGJ2 on DSS-induced phosphorylation of STAT3 (Figure 6B) and COX-2 expression (Figure 6C) were verified by immunohistochemical analysis and immunofluorescence staining, respectively. Likewise, expression of representative pro-inflammatory cytokines was significantly reduced by 15d-PGJ2 administered during the resolution phase (Figure 6D).

DISCUSSION

Acute inflammation is a protective immune reaction against microbial infection and tissue injury (37). After its completion of critical function in host defense, acute inflammation should be properly resolved to avoid chronic inflammation responsible for the pathogenesis of many prevalent disorders, such as cancer, obesity, and IBD (38). In this study, we investigated the resolution of intestinal inflammation by using a DSS-induced murine colitis model that mimics the characteristics of human IBD (2, 39). The onset and termination of acute intestinal inflammation are coordinate regulated by endogenous checkpoints to avoid progression to chronic inflammation. The two contrasting processes are finely orchestrated by endogenous pro-inflammatory and pro-resolving mediators (40, 41).

PGs are key lipid mediators/modulators derived from arachidonic acid that have diverse functions in resolution of inflammation. It has been reported that some of pro-inflammatory PGs generated in inflamed tissue amplify acute inflammation, whereas anti-inflammatory/pro-resolving PGs, such as 15d-PGJ2, promote proper termination of inflammation (26, 42–44). Although 15d-PGJ2 is detected in self-resolving exudates, the molecular mechanism underlying its pro-resolving effects on intestinal inflammation remains poorly understood. In our present study, pharmacologic inhibition of 15d-PGJ2 production impaired resolution of DSS-induced murine colitis. Conversely, administration of exogenous 15d-PGJ2 promoted resolution of intestinal inflammation through its immunomodulatory and anti-inflammatory effects.

Resolution of inflammation is an active process that requires inhibition of further leukocyte recruitment and elimination of leukocytes from inflamed sites. As part of the gut inflammatory response, neutrophils recruited to the inflamed site are activated and undergo oxidative burst, a critical event in the host defense. This leads to overproduction of reactive oxygen species (ROS) with which the neutrophils kill and eliminate the infectious pathogens (45–47). Therefore, infiltrated neutrophils are essential for host defense against invading pathogens, but excessive neutrophil infiltration is limited and neutrophils eventually die via apoptosis. Accelerated neutrophil apoptosis has severe pathological consequences such as infection and autoimmune diseases (48–50). On the other hand, delayed neutrophil apoptosis causes inflammatory disorders like chronic pulmonary obstructive disease, and rheumatoid arthritis (51–53).

It has been reported that 15d-PGJ2 promotes endothelia cell apoptosis as well as granulocyte apoptosis (54, 55). Furthermore,
15d-PGJ2 induces synoviocyte apoptosis and suppresses arthritis in rats (55). In this study, we found that 15d-PGJ2 inhibited neutrophil infiltration during the resolution phase of inflammation. We speculate that 15d-PGJ2 might regulate not only excessive neutrophil infiltration into inflamed area, but also neutrophil apoptosis, thereby promoting the resolution of intestinal inflammation.

IBD is characterized by persistent infiltration of inflammatory immune cells including neutrophils and macrophages within the gut and in the circulation (56). In particular, intestinal macrophages contribute to the gut homeostasis by balancing pro-inflammatory and anti-inflammatory cytokines (57). The M1 macrophages produce pro-inflammatory cytokines and oxidative stress, resulting in initiation and progression of inflammation, while the M2 macrophages exert anti-inflammatory and pro-resolving functions, thereby promoting resolution of intestinal inflammation (31). It has been reported that phenotypic switching from M1 macrophages to the M2 macrophages plays a critical role in the resolution of inflammation and tissue repair (58, 59). The number of M1 macrophages which release pro-inflammatory cytokines is increased in the colonic tissue of IBD patients (59–61). We have found that 15d-PGJ2 counteracts excessive inflammatory responses and stimulates resolution of colitis in the colon of DSS-treated mice by regulating macrophage polarization. However, macrophage polarization during different phases of the inflammatory and resolving processes is not a fixed but a dynamic process in which macrophages exhibit a high degree of plasticity, existing in different intermediate forms of activation (62). Therefore, more precise assessment of the profiles of different forms of macrophages merits further investigation to better understand the 15d-PGJ2-mediated resolution of intestinal inflammation.

A diverse of transcription factors including STAT3, NF-κB, AP-1, and PPARγ are involved in M1 or M2 macrophage polarization (63). PPARγ plays a key role in inflammation by regulating both M1 and M2 polarization. PPARγ negatively regulated NF-κB and AP-1 signaling, resulting in inhibition of M1 macrophage polarization. In contrast, PPARγ was also found to mediate M2 polarization by inducing Arg-1 and CD36 expression (63, 64). Though the role for PPARγ in IBD is controversial (65), a plethora of studies suggest that PPARγ activation might impede pathophysiological imbalances associated with IBD (66). 15d-PGJ2, as an endogenous PPARγ ligand, has been reported to inhibit pro-inflammatory signaling (16, 67). Pretreatment with PPARγ agonists 15d-PGJ2 and rosiglitazone prevented acute stress-induced colonic inflammation and barrier dysfunction in rats, and these effects were reverted by a PPARγ specific antagonist (68). However, a recent study by Takagi and colleagues reveals that 15d-PGJ2 inhibits development of intestinal inflammation in mice via PPARγ-independent and Nrf2-heme oxygenase-dependent mechanisms (69).

Overproduction of IL-6 has been considered as a result of failure in resolution of intestinal inflammation. It is clearly defined that incomplete intestinal resolution leads to IBD (5, 70). IL-6 production by lamina propria macrophages and CD4+ T cells was increased in experimental colitis and in patients with IBD (71, 72). Blockade of IL-6 signaling with a neutralizing monoclonal antibody was effective in suppressing chronic intestinal inflammation in mouse models (71, 73). In the present study, we notably found that intraperitoneal injection of exogenous 15d-PGJ2 reduced the proportion of macrophages...
expressing IL-6. 15d-PGJ2 contains a reactive \( \alpha, \beta \)-unsaturated carbonyl present in the cyclopentenone ring and hence can form covalent adducts with the cysteine thiol of intracellular regulatory proteins (74, 75). We have recently reported that 15d-PGJ2 covalently binds to the cysteine 259 of STAT3 and inhibits its activation (76). We also found that COX-2 expression during the resolution period was inhibited by administration of exogenous 15d-PGJ2. This may be 'resolution-toxic' (40) as the COX-2 activity is responsible for the production of PGD2, a precursor of 15d-PGJ2. Therefore, it is likely that excessive amounts of 15d-PGJ2 can block the further synthesis of this proresolving mediator, constituting a negative-feedback loop for the self-limited resolution.

In conclusion, our findings suggest that 15d-PGJ2, generated during inflammatory process, stimulates the resolution of experimentally induced intestinal inflammation by inducing M2 macrophage polarization (Figure 7). 15d-PGJ2 administration decreased the proportion of M1 macrophages and macrophages expressing IL-6, which accounts for its inhibition of STAT3 activation. Unresolved inflammation caused by inappropriate macrophage polarization can result in inflammation-associated disorders like IBD, diabetes, and arthritis (63, 77). Regulating macrophage polarization is a crucial process in resolving inflammation, thereby, preventing the development of chronic inflammatory disorders. 15d-PGJ2, generated during resolution of intestinal inflammation, is one of the prime endogenous proresolving molecules and this lipid mediator might have a therapeutic potential in the management of IBD associated with macrophage dysfunction.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee at Seoul National University, South Korea.

AUTHOR CONTRIBUTIONS

WK conceived and designed the study. J-HJ, XZ, and HS provided the technical support. WK drafted the article.
SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.615803/full#supplementary-material

Supplementary Figure 1 | Gating for lamina propria immune cells. Lamina propria immune cells were isolated from the colon of no DSS group, inflammation phase group and resolution phase group. (A) Lamina propria immune cells are stained with CD45, CD11b, Gr-1, F4/80, CD206, CD86 antibodies and then gate on the cells of interest according to the manufacturer’s protocol. (B) The number and the percentage of total immune cells (CD45+) in the lamina propria of mice were determined by flow cytometry. All data represent mean ± S.D. (n=8), *p < 0.05 and **p < 0.001.

Y-JS supervised the work and edited the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by the Global Core Research Center (GCRC) grant (No. 2011-0030001) and the BK21 FOUR Program (5120200513755) from the National Research Foundation, Republic of Korea.

REFERENCES

1. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut (2013) 62:1653–64. doi: 10.1136/gutjnl-2012-303955
2. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol (2010) 28:573–621. doi: 10.1146/annurev-immunol-030409-101225
3. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol (2011) 11:19–20. doi: 10.1038/nri2891
4. Lee SH, Starkey PM, Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J Exp Med (1985) 161:475–89. doi: 10.1084/jem.161.3.475
5. Vine AM, Loke P. Intestinal macrophages in resolving inflammation. J Immunol (2019) 203:593–9. doi: 10.4049/jimmunol.1900345
6. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 140:1768–73. doi: 10.1053/j.gastro.2011.02.047
7. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol (2008) 14:4285–8. doi: 10.3748/wjg14.4.11280
8. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med (2009) 206:1465–72. doi: 10.1084/jem.20082683
9. Levy DE, Darnell J Fr1. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 3:651–62. doi: 10.1038/nrm909
10. Aggarwal BB, Kunnmannakka AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, peroxisome proliferator-activated receptor (PPAR) gamma. Contribution of cyclopentenone prostaglandins to the resolution of inflammation, role of STAT3 in IBD. Annu Rev Immunol (2007) 25:753–82. doi: 10.1146/annurev.immunol.25.022806.144571
11. Bromberg J, Wang TC. Inflammation and cancer: how intimate is the relationship? Nat Rev Mol Cell Biol (2005) 6:240–5. doi: 10.1038/nrm1632
12. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al.贡献 of 15-deoxy-D12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptor-gamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-alpha-induced gene expression. Arterioscler Thromb Vasc Biol (2005) 25:710–6. doi: 10.1161/01.ATV.0000154862.76228.d1
13. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammation lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol (2002) 2:787–95. doi: 10.1038/nri7915
14. Hertelano S, Castrillo A, Alvarez AM, Bosca L. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J Immunol (2000) 165:6525–31. doi: 10.4049/jimmunol.165.11.6525
15. Rossi A, Kapahi P, Naotli G, Takahashi T, Chen Y, Karin M. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkB kinase. Nature (2000) 403:103–8. doi: 10.1038/3574720
16. Mochizuki M, Ishii Y, Ito Kh, Iizuka T, Morishima Y, Kimura T, et al. Role of 15-deoxy-D12,14-prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. Am J Respir Crit Care Med (2005) 171:1260–6. doi: 10.1164/rccm.200406-7550OC
17. Weigmann B, Hubbe I, Seidl D, Nicolaev A, Becker C, Neurath MF. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc (2007) 2:2307–11. doi: 10.1038/nprot.2007.315
18. Park YH, Kim N, Shim YK, Choi YJ, Nam RH, Choi YJ, et al. Adequate dextran sodium sulfate-induced colitis model in mice and effective outcome measurement method. J Cancer Prev (2015) 20:260–7. doi: 10.15430/JCP.2015.20.4.260
19. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation: ‘Arterioscler Thromb Vasc Biol (2011) 31:986–1000. doi: 10.1161/ATVBAHA.110.207449
20. Rajakaruar R, Yaqoob MM, Gilroy DW. COX-2 in inflammation and resolution. Mol Interv (2008) 6:199–207. doi: 10.1124/mi.6.4.6
21. Gandhi UH, Kaushal N, Ravindra KC, Hegde S, Nelson SM, Narayan V, et al. Selenoprotein-dependent up-regulation of hematopoietic prostaglandin D2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) gamma. J Biol Chem (2011) 286:27471–82. doi: 10.1074/jbc.M111.260547
22. Virtue S, Masoodi M, de Weijer BA, van Eijk M, Mok CY, Eiden M, et al. Prostaglandin profiling reveals a role for haematopoietic prostaglandin D synthase in adipose tissue macrophage polarisation in mice and humans. Int J Obes (Lond) (2015) 39:1151–60. doi: 10.1038/ijo.2015.34
23. Aritake K, Kado Y, Inoue T, Miyano M, Urade Y. Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem (2006) 281:15277–86. doi: 10.1074/jbc.M506431200
24. Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity (2016) 44:450–62. doi: 10.1016/j.immuni.2016.02.015
25. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity (2010) 32:593–604. doi: 10.1016/j.immuni.2010.05.007
26. Egger B, Bajaj-Elliott M, MacDonald TT, Inglis R, Eysselin VE, Buchler MW. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion (2000) 62:240–8. doi: 10.1159/000078622
33. Garside P. Cytokines in experimental colitis. Clin Exp Immunol (1999) 118:337–9. doi: 10.1046/j.1600-2249.1999.01088.x
34. Nguyen PM, Putoczki TL, Ernst M. STAT3-activating cytokines: A therapeutic opportunity for inflammatory bowel disease? J Interferon Cytokine Res (2013) 35:340–50. doi: 10.1089/jir.2014.0225
35. Wang D, Dubois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene (2009) 28:781–8. doi: 10.1038/onc.2009.421
36. Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology (2004) 113:427–37. doi: 10.1111/j.1365-2567.2004.01984.x
37. Shinohara M, Serhan CN. Novel endogenous proresolving molecules: Essential fatty acid-derived and gaseous mediators in the resolution of inflammation. J Atheroscler Thromb (2016) 23:635–64. doi: 10.5551/jat.10128
38. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 21:325–32. doi: 10.1096/fj.06-7277rev
39. Perse M, Cerar A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol (2012) 2012:718617. doi: 10.1155/2012/718617
40. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Ann Rev Immunol (2007) 25:101–37. doi: 10.1146/annurev.immunol.25.032206.141647
41. Fiocchi C. What is “physiological” intestinal inflammation and how does it differ from “pathological” inflammation? Inflammation Bowel Dis (2008) 14(Suppl. 2):S77–80. doi: 10.1002/ibd.20618
42. Scher JU, Pillinger MH. The anti-inflammatory effects of prostaglandins. J Invest Med (2009) 57:703–8. doi: 10.2310/JIM.0b013e31819a7a26
43. Trivedi SG, Newson J, Rajakariar R, Jacques TS, Hannon R, Kanaoka Y, et al. Serotonin is a survival factor for neutrophils in rheumatoid synovial fluid. J Immunol (2001) 168:6232–43. doi: 10.4049/jimmunol.168.12.6232
44. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammation Bowel Dis (2006) 12(Suppl 1):S3–9. doi: 10.1097/01.MIB.0000195385.19268.68
45. Kuhl AA, Erben U, Kreidel LI, Siegmann B. Diversity of intestinal macrophages in inflammatory bowel diseases. Front Immunol (2015) 6:613. doi: 10.3389/fimmu.2015.00613
46. Shahbod F, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and monocyte-macrophage activation in atherosclerosis. J Immunol (Lond) (2011) 89. doi: 10.1186/1476-9255-8-9
47. Tanabasi M. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol (2010) 10:36–46. doi: 10.1038/nri2675
48. Berndt BE, Zhang M, Chen GH, Hugnangle GB, Kao JY. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J Immunol (2007) 179:6255–62. doi: 10.4049/jimmunol.179.9.6255
49. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest (1994) 94:499–53. doi: 10.1172/JCI17345
50. Murray PJ. Macrophage activation. Ann Rev Physiol (2017) 79:541–66. doi: 10.1146/annurev-physiol-022516-034339
51. Liu YC, Zou XB, Chai YF, Yao YM. Macrophage polarization in inflammatory diseases. Int J Biol Sci (2014) 10:520–9. doi: 10.7150/ijbs.8879
52. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature (1998) 391:79–82. doi: 10.1038/31478
53. Wu GD. Is there a role for PPARγ in IBD? Yes, no, maybe. Gastroenterology (2003) 124:1538–42. doi: 10.1016/S0016-5085(03)00345-7
54. Decara J, Rivera P, López-Gamiero AB, Serrano A, Pavin FJ, Baixeras E, et al. Peroxisome proliferator-activated receptors: Experimental targeting for the treatment of inflammatory bowel diseases. Front Pharmacol (2020) 11:730. doi: 10.3389/fphar.2020.00730
55. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 391:82–6. doi: 10.1038/31484
56. Ponferrada A, Colo JR, Alou L, Somoza D, Mozo MA, et al. The role of PPARγ on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology (2007) 132:1791–803. doi: 10.1053/j.gastro.2007.02.032
57. Takagi T, Naito Y, Mizushima K, Hirai Y, Kamada K, Uchiyama K, et al. 15-Deoxy-Δ12,14-prostaglandin J2 ameliorates dextran sulfate sodium-induced colitis in mice through heme oxygenase-1 induction. Arch Biochem Biophys (2019) 677:10183. doi: 10.1016/j.abb.2019.10183
58. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med (2006) 351:2066–78. doi: 10.1056/NEJMra060467
59. Attreya R, Muder J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans-signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med (2000) 6:638–83. doi: 10.1038/75068
60. Kai Y, Takahashi I, Ishikawa H, Hiroi T, Mizushima T, Matsuoka C, et al. Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology (2005) 128:922–34. doi: 10.1053/j.gastro.2005.01.013
61. Yamamoto M, Yoshizaki K, Kishimoto T, Iso H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol (2000) 164:4878–82. doi: 10.4049/jimmunol.164.94878
62. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev (2001) 21:185–210. doi: 10.1002/med.1006
63. Kim EH, Surh YJ. 15-deoxy-Δ12,14-prostaglandin J2 as a potential endogenous regulator of retinoic-sodium transcription factors. Biochem Pharmacol (2006) 72:2516–28. doi: 10.1016/j.bcp.2006.07.030
64. Kim SJ, Cho NC, Han B, Kim K, Hahn YI, Kim KP, et al. 15-Deoxy-Δ12,14-prostaglandin J2 binds and inactivates STAT3 in H-Ras transformed human breast epithelial cells. FEBS Lett (2021). doi: 10.1016/j.febslet.2017.04.20073
65. Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG. Prostaglandin D2, and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of caspase degradation using a peroxisome proliferator-activated receptor-γ-dependent mechanism. J Immunol (2002) 168:6232–43. doi: 10.4049/jimmunol.168.12.6232
77. Korns D, Frasch SC, Fernandez-Boyanapalli R, Henson PM, Bratton DL. Modulation of macrophage efferocytosis in inflammation. *Front Immunol* (2011) 2:57. doi: 10.3389/fimmu.2011.00057

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.